NA Proactive news snapshot: Mountain Valley MD, AIM ImmunoTech, Atlas Engineered Products ...

Mountain Valley MD Holdings Inc. (CSE:MVMD) (FRA:20MP) said it has filed for an accelerated review of its macrocyclic lactone solubilization patent with the United States Patent and Trademark Office (USPTO). To support the accelerated patent examination request, the company said it has provided the USPTO with new formulation analyses of different diluted concentrations of its Quicksol Ivermectin in solution, data that the company had fast-tracked for completion and validation by a third-party contract research organization (CRO). AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) announced Thursday that it has received approval from the Institutional Review Board (IRB) to notify the public of potential openings in its Ampligen Expanded Access Program for coronavirus patients. The Ampligen EAP protocol is authorized to enroll up to 100 active trial participants, 20 of whom can be long-haulers, a subset of coronavirus patients with symptoms that can extend for months. The program is being conducted by Charles Lapp at Hunter-Hopkins Center in Charlotte, North Carolina and Daniel Peterson at Sierra Internal Medicine in Incline Village, Nevada. Enrollment is an important milestone in AIM's program to develop Ampligen as a therapy for those who will suffer from SARS-CoV-2-induced chronic fatigue, including many with brain fog. Atlas Engineered Products Ltd. (CVE:AEP) (OTCMKTS:APEUF) said it has signed a new credit and banking agreement with TD Canada Trust. The new credit facilities include a C$2.0 million uncommitted revolving line of credit, a C$4.8 million reducing term loan, a C$5.5 million committed revolving line of credit, and a C$2.0m non-revolving equipment leasing line. In a statement, Atlas Engineered Products CEO & president, Dirk Maritz said: "We are excited with this new financing and credit partnership with TD Canada Trust of up to C$14.3 million." DGTL Holdings Inc. (CVE:DGTL) (OTCQB:DGTHF) (FRA:A2QB0L) has announced the closing of the first tranche of the non-brokered private placement it announced on November 25, 2020, and updated on December 17, 2020. In the first tranche, the company raised aggregate gross proceeds of $1,116,385 by the issue and sale of 3,189,670 common shares at a price of $0.35 each. The company plans to close the balance of the offering in a second tranche. DGTL said it intends to use the proceeds of the offering to develop the software of its wholly-owned subsidiary, Hashoff LLC, to service the fastest-growing multimedia social media application markets. Specifically, the company will finance the software development of the Hashoff SaaS (software-as-a-service) technology platform to service digital media platforms such as TikTok, Snapchat, Twitch, Triller, Reels and others, and for general working capital purposes. In connection with the first tranche, the company paid aggregate cash finder's fees of $15,876 to arm's length finders. All securities issued in the first tranche of the offering are subject to a statutory hold period expiring on April 23, 2020. Aurania Resources Ltd. (CVE:ARU) (OTCQB:AUIAF) (FRA:20Q) has announced with great sadness the passing of Independent Director, Dr Leanne Baker, on December 22, 2020, after she lost her courageous battle with cancer. Dr Baker had served as a director of the company since June 2019 and was a member of Aurania's Audit Committee. The group said Dr Baker was a valuable sounding-board for management and her loss will be keenly felt, adding its sincere condolences to her family at this time. Aurania's chairman & CEO, Dr Keith Barron commented: "Leanne was a true asset to our Company as well as a friend and colleague of mine for almost twenty years. She will be remembered for her calm professionalism, guidance, and wealth of knowledge, particularly regarding Corporate Governance." Aequus Pharmaceuticals Inc. (CVE:AQS) (OTCQB:AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, has unveiled a holiday message to shareholders from its CEO, Doug Janzen. In it he said: "As we approach the final days of 2020, we would like to recognize the dedication and resilience of our team, who have worked diligently to achieve major milestones and continued growth for Aequus, while overcoming unprecedented challenges. Together we have added additional products to our commercial pipeline and became exceptionally agile in reaching our customers and creating growth, despite the changing pandemic-related restrictions throughout Canada." The CEO concluded: "Aequus is well funded and well-positioned to accelerate growth during the next 12 months and beyond." Algernon Pharmaceuticals Inc. (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF), a clinical-stage pharmaceutical development company said it has elected to exercise its acceleration right governing the common share purchase warrants issued on November 1, 2019. Under the terms of the warrant indenture, the company may accelerate the expiry date of the November warrants when the daily volume-weighted average (VWAP) trading price of its common shares exceeds $0.35 for the preceding 20 consecutive trading days on the Canadian Securities Exchange. As of the close of markets on December 11, 2020, this has occurred. Accordingly, the expiry date of the November Warrants is accelerated to January 21, 2021. As of Thursday's date, there are approximately 6.5 million November Warrants that have not yet been exercised, the group said. Arizona Silver Exploration Inc (CVE:AZS) said the TSX Venture Exchange has accepted for filing documentation with respect to its non-brokered private placement announced December 10, 2020, and December 23, 2020, which will see the issue of 4,899,382 shares at a purchase price of 35 cents each, plus 2,449,689 share purchase warrants with an exercise price of 55 cents for a five-year period with 16 placees. Goldcore Resources Ltd (CVE:GEM) said the TSX Venture Exchange has accepted for filing a share purchase agreement dated October 27, 2020, between Goldcore, Hugh Oswald, Graeme Sewell and Connor Yuen, whereby the company has acquired the issued and outstanding shares of Bench Minerals Corp., the sole asset of which are mineral claims known as the Stallion project in the Golden Horseshoe region, located in British Columbia. The consideration is four million common shares and $15,000 cash. Recruiter.com Group, Inc. (OTCQB:RCRT), a leading hiring platform with the world's largest network of small and independent recruiters, has announced that an interview with Evan Sohn, its chairman and CEO, will air this Sunday, December 27, 2020, on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6pm local time in every country in Europe on Bloomberg International. In the exclusive interview, Sohn discusses the Recruiter.com mission of disrupting the $120 billion recruiting and staffing industry, major account wins, growth plans, and more. To view the interview segment, investors can visit: https://youtu.be/FcRwk-unPoI